US17248W1053 - Common Stock
0.72 +0.04 (+5.91%)
After market: 0.6902 -0.03 (-4.14%)
NASDAQ:CING (9/28/2023, 7:00:00 PM)After market: 0.6902 -0.03 (-4.14%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 15 full-time employees. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improve the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).
1901 W. 47Th Place
Kansas City KANSAS
Presentation on Wednesday, October 4th at 02:30 PM PT...
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a...
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a...
CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S)...
Conversion Follows $1.0 Million Capital Investment in August 2023...
Data Accepted as Finalist for First Annual Poster Awards
Here you can normally see the latest stock twits on CING, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.